2. Signaling Pathways
  3. Neuronal Signaling
  4. CaMK

CaMK

Calmodulin-dependent protein kinases; Calmodulin-dependent kinases

CaMK

Related Products

PDF 0.47 MB

The Ca2+/calmodulin-dependent kinase (CaMK) family has been recognized as a key mediator in living organisms and various biological processes.

CaMK II is a multifunctional cytoplasmic calcium and calmodulin-dependent protein kinase that phosphorylates and alters the function of a variety of substrates. The CaMK II pathway has been found to regulate the RANKL-induced osteoclast formation via the cAMP-response element binding protein (CREB) pathway.

Among many signaling pathways of proliferation, intracellular calciumol/L has been extensively demonstrated to be very important. In cytoplasm, calciumol/L binds to calmodulin, and then activates the CaMKs which are a family of structurally related serine/threonine protein kinases including CaMKI-IV. CaMKII, a multi functional protein kinase, is ubiquitously involved in many physiological processes including control of cell cycle, apoptosis, gene expression, and neurotransmission.

CaMK Isoform Specific Products:

CaMK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0532AS
    Trifluoperazine-d3 dihydrochloride
    		Inhibitor
    Trifluoperazine-d3 (dihydrochloride) is deuterium labeled Trifluoperazine (dihydrochloride). Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis.
    Trifluoperazine-d<sub>3</sub> dihydrochloride
  • HY-P5987
    Calmodulin Kinase IINtide, Myristoylated
    		Inhibitor
    Calmodulin Kinase IINtide, Myristoylated (Myr-CaMKIINtide) is a selective and noncompetitive inhibitor of CaMKII.
    Calmodulin Kinase IINtide, Myristoylated
  • HY-177720
    eEF2K degrader-2
    		Degrader
    eEF2K degrader-2 (Compound C1) is a molecular glucose degrading agent that targets the eEF2K protein. eEF2K degrader-2 can significantly inhibit the proliferation, migration, invasion and induce apoptosis of triple negative breast cancer (TNBC) cells. eEF2K degrader-2 has no obvious organ toxicity or pathological damage. eEF2K degrader-2 can be used in the research of cancer such as breast cancer.
    eEF2K degrader-2
  • HY-P1479
    Calmodulin-Dependent Protein Kinase II (290-309)
    Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.
    Calmodulin-Dependent Protein Kinase II (290-309)
  • HY-108599R
    DCP-LA (Standard)
    		Activator
    DCP-LA (Standard) is the analytical standard of DCP-LA. This product is intended for research and analytical applications. DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis[1][2][3].
    DCP-LA (Standard)
  • HY-P10282
    Synapsin I-(3-13)
    Synapsin I-(3-13), a substrate for CaMK1, is a glycoprotein. Synapsin I is a phosphoprotein that coats the cytoplasmic side of synaptic vesicles and regulates their trafficking within nerve terminals.
    Synapsin I-(3-13)
  • HY-P3811
    Autocamtide-3
    Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective CaMKII (Ca2+/calmodulin-dependent kinase II) (CaMK) substrate.
    Autocamtide-3
  • HY-134261
    8-Br-ADPR
    		Inhibitor
    8-Br-ADPR (8-Bromoadenosine-5'-O-diphosphoribose) is a TRPM2 inhibitor and ADPR signaling pathway antagonist. 8-Br-ADPR inhibits glucagon-mediated nuclear calcium signaling and downstream CaMKII/CREB phosphorylation by blocking ADPR-induced TRPM2 activation. 8-Br-ADPR significantly reduces gluconeogenic gene expression and blood glucose levels in diabetic models. 8-Br-ADPR effectively blocks ADPR-mediated calcium signal transduction in NK cells, inhibits immune synapse formation, granzyme B release and cytolytic activity against melanoma cells. 8-Br-ADPR is widely used in studies related to diseases such as diabetes, melanoma and lymphoma.
    8-Br-ADPR
  • HY-135167
    HOCPCA
    HOCPCA is a compound with neuroprotective activity that improves sensorimotor function in mice after experimental stroke. HOCPCA selectively binds to the CaMKIIα hub domain, modulates signaling of different CaMKII pools, and alleviates abnormal CaMKII signaling after cerebral ischemia. HOCPCA promotes hippocampal neuronal activity and enhances working memory. HOCPCA also normalizes Thr286 autophosphorylation in the cytoplasm after ischemia and downregulates ischemia-specific expression of active CaMKII enzymatic cleavage fragments. HOCPCA binds to the GHB binding site with 27-fold higher affinity than GHB and has good blood-brain barrier penetration ability.
    HOCPCA
  • HY-N1988R
    Cucurbitacin IIa (Standard)
    		Inhibitor
    Cucurbitacin IIa (Hemslecin A) (Standard) is the analytical standard for Cucurbitacin IIa (HY-N1988). This product is used for research and analytical applications. Cucurbitacin IIa is an orally active, blood-brain barrier-penetrating EGFR inhibitor with an IC50 of 1.455 nM for human EGFR. Cucurbitacin IIa induces caspase-3 dependent cell apoptosis, downregulates survivin expression, enhances autophagy levels, disrupts the actin cytoskeleton through actin aggregation, blocks the cell cycle at the G2/M phase, and inhibits the EGFR-MAPK signaling pathway to exert anti-inflammatory activity. Cucurbitacin IIa can be used in research on inflammatory-related diseases, depression, and non-small cell lung cancer and other cancers.
    Cucurbitacin IIa (Standard)
  • HY-E70810
    CaMK1β Recombinant Human Active Protein Kinase
    CaMK1 is present in several cell types and may be involved in various cellular processes. CaMK1 exists as different isoforms (α, β, γ and δ). CaMK1β Recombinant Human Active Protein Kinase is obtained by expressing CaMK1β proteins.
    CaMK1β Recombinant Human Active Protein Kinase
  • HY-19230
    DY-9760e
    		Inhibitor
    DY-9760e is a calmodulin (CaM) inhibitor. DY-9760e selectively inhibits the activity of various calmodulin-dependent enzymes by antagonizing the Ca²⁺/CaM complex, exhibiting the strongest inhibitory activity against nNOS, CaM kinase II, and calcineurin (Ki: 0.9, 1.4, and 2.0 μM, respectively). DY-9760e inhibits excessive nitric oxide production and protein tyrosine nitration, as well as the activation of calpain and caspase-3. DY-9760e reduces infarct size, improves cardiac function, and inhibits oxidative stress and cell death. DY-9760e can be used in research on the treatment of myocardial infarction, cerebral ischemia, and other diseases.
    DY-9760e
  • HY-E70812
    CaMK2β Recombinant Human Active Protein Kinase
    CAMK2 is involved in the regulation of cellular processes in a variety of tissues. CaMK2β Recombinant Human Active Protein Kinase is obtained by expressing CaMK2β proteins.
    CaMK2β Recombinant Human Active Protein Kinase
  • HY-E70811
    CaMK2α Recombinant Human Active Protein Kinase
    CAMK2 is involved in the regulation of cellular processes in a variety of tissues. CaMK2α Recombinant Human Active Protein Kinase is obtained by expressing CaMK2α proteins.
    CaMK2α Recombinant Human Active Protein Kinase
  • HY-P10499
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors.
    [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302)
  • HY-P5525
    AC3-I, myristoylated
    		Inhibitor
    AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)
    AC3-I, myristoylated
  • HY-P10071
    CaMKII inhibitory peptide KIIN
    		Inhibitor
    CaMKII inhibitory peptide KIIN is a potent inhibitor of CaMKII.
    CaMKII inhibitory peptide KIIN
  • HY-176149
    Fluoxetine-Conjugated Platinum(IV) prodrug-1
    		Inhibitor
    Fluoxetine-Conjugated Platinum(IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum(IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum(IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research.
    Fluoxetine-Conjugated Platinum(IV) prodrug-1
  • HY-P11226
    TI-16
    		Activator
    TI-16 is a peptide that targets β-amyloid (Aβ) protein. TI-16 can cross the blood-brain barrier. TI-16 can increase the concentration of intracellular free CaM, thereby restoring calcium ion homeostasis and reducing Aβ toxicity. TI-16 can reduce the deposition of Aβ in the brain, improve neuronal pathology, inhibit cell apoptosis, and improve cognitive function in mice. TI-16 is commonly used in the study of Alzheimer's disease.
    TI-16
  • HY-162860
    FO-4-15
    		Activator 99.45%
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage.
    FO-4-15
Cat. No. Product Name / Synonyms Application Reactivity
CaMK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.